FI941580A0 - Bicykliska ansamyciner - Google Patents

Bicykliska ansamyciner

Info

Publication number
FI941580A0
FI941580A0 FI941580A FI941580A FI941580A0 FI 941580 A0 FI941580 A0 FI 941580A0 FI 941580 A FI941580 A FI 941580A FI 941580 A FI941580 A FI 941580A FI 941580 A0 FI941580 A0 FI 941580A0
Authority
FI
Finland
Prior art keywords
ansamycins
bicyclic
bicyclic ansamycins
compounds
formuladefined
Prior art date
Application number
FI941580A
Other languages
English (en)
Finnish (fi)
Other versions
FI106028B (sv
FI941580A (sv
Inventor
Rodney C Schnur
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI941580A0 publication Critical patent/FI941580A0/sv
Publication of FI941580A publication Critical patent/FI941580A/sv
Application granted granted Critical
Publication of FI106028B publication Critical patent/FI106028B/sv

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FI941580A 1993-04-07 1994-04-06 Förfarande för framställning av terapeutiskt användbara bicykliska geldanamysinderivat FI106028B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4452193 1993-04-07
US08/044,521 US5387584A (en) 1993-04-07 1993-04-07 Bicyclic ansamycins

Publications (3)

Publication Number Publication Date
FI941580A0 true FI941580A0 (sv) 1994-04-06
FI941580A FI941580A (sv) 1994-10-08
FI106028B FI106028B (sv) 2000-11-15

Family

ID=21932854

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941580A FI106028B (sv) 1993-04-07 1994-04-06 Förfarande för framställning av terapeutiskt användbara bicykliska geldanamysinderivat

Country Status (10)

Country Link
US (1) US5387584A (sv)
EP (1) EP0693073B1 (sv)
JP (1) JP2722280B2 (sv)
AT (1) ATE166877T1 (sv)
CA (1) CA2160137C (sv)
DE (1) DE69410790T2 (sv)
DK (1) DK0693073T3 (sv)
ES (1) ES2116594T3 (sv)
FI (1) FI106028B (sv)
WO (1) WO1994022867A1 (sv)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852496B1 (en) 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
US6747055B1 (en) * 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
CA2338000C (en) 1998-07-17 2009-12-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-soluble 4-thio-maleimido derivatives and methods for their production
JP2002531513A (ja) * 1998-12-07 2002-09-24 エコスマート テクノロジーズ,インコーポレーテッド 天然植物精油をシグナル伝達調節物質とともに用いた癌治療薬配合物および方法
CA2417495C (en) * 2000-07-28 2013-04-30 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
KR20030065502A (ko) 2000-11-02 2003-08-06 슬로안-케테링인스티튜트퍼캔서리서치 에이치에스피90 저해제를 이용한 세포독성 제제의 효능을향상시키는 방법
AU2002228771B2 (en) * 2000-11-02 2007-10-25 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to HSP90
CA2440809A1 (en) * 2001-03-01 2002-09-12 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
JP2004529188A (ja) * 2001-05-23 2004-09-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 上昇に関連した癌の治療法
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
EP1923061A1 (en) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
WO2003026571A2 (en) * 2001-09-24 2003-04-03 Conforma Therapeutics Corporation Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
DE60327994D1 (de) * 2002-02-08 2009-07-30 Conforma Therapeutics Corp Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
US20060014730A1 (en) * 2002-04-10 2006-01-19 Conforma Therapeutics Corporation Ansamycin formulations and methods for producing and using same
US20060148776A1 (en) * 2003-03-13 2006-07-06 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20050026893A1 (en) * 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US7691838B2 (en) * 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050054625A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050054589A1 (en) * 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
WO2005009345A2 (en) * 2003-06-13 2005-02-03 Kosan Biosciences, Inc. 2-desmethyl ansamycin compounds
CN100404029C (zh) * 2003-09-25 2008-07-23 中国医学科学院医药生物技术研究所 格尔德霉素(c-3559)在制备疱疹病毒生殖道感染药物中的应用
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
WO2005056531A1 (en) 2003-11-12 2005-06-23 Kosan Biosciences, Inc. 11-o-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
CA2547343C (en) 2003-12-23 2013-05-14 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US7491701B2 (en) * 2004-01-27 2009-02-17 Boys Town National Research Hospital Peptides that bind to HSP90 proteins
US20080171687A1 (en) * 2004-09-16 2008-07-17 Abraxis Bioscience, Inc. Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
US20060067953A1 (en) * 2004-09-29 2006-03-30 Conforma Therapeutics Corporation Oral pharmaceutical formulations and methods for producing and using same
US7544672B2 (en) * 2005-03-30 2009-06-09 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
EP1871361A2 (en) * 2005-04-07 2008-01-02 Conforma Therapeutics Corporation Phospholipid-based pharmaceutical formulations and methods for producing and using same
KR20080007642A (ko) * 2005-04-29 2008-01-22 코산 바이오사이언시즈, 인코포레이티드 프로테아좀 억제제와 함께 17-aag 또는 17-ag 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법
AU2006242540A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG of 17-AG of a prodrug of either
US20080032719A1 (en) * 2005-10-01 2008-02-07 Outland Research, Llc Centralized establishment-based tracking and messaging service
WO2007002093A2 (en) * 2005-06-21 2007-01-04 Infinity Discovery, Inc. Ansamycin formulations and methods of use thereof
WO2008020815A1 (en) 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
AU2006320435A1 (en) * 2005-12-01 2007-06-07 Conforma Therapeutics Corporation Compositions containing ansamycin
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
WO2008094438A1 (en) 2007-01-26 2008-08-07 Kosan Biosciences Incorporated Macrolactams by engineered biosynthesis
WO2008128063A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
CN101668426B (zh) * 2007-04-12 2014-01-15 焦阳特制药股份有限公司 可用作抗癌药的smac模拟二聚体和三聚体
KR20100074177A (ko) 2007-09-10 2010-07-01 유니버시티 오브 매사추세츠 미토콘드리아-표적화된 항-종양 물질
US7960420B2 (en) * 2007-12-21 2011-06-14 Joyant Pharmaceuticals, Inc Diazonamide analogs with improved solubility
WO2009105044A1 (en) 2008-02-22 2009-08-27 Agency For Science, Technology And Research (A*Star) Mesenchymal stem cell particles
WO2009116951A2 (en) 2008-03-17 2009-09-24 Agency For Science, Technology And Research Microcarriers for stem cell culture
AU2009243056B2 (en) * 2008-04-29 2015-05-14 Joyant Pharmaceuticals, Inc. Indoline anti-cancer agents
WO2009143485A1 (en) * 2008-05-22 2009-11-26 Joyant Pharmaceuticals, Inc. Diazonamide analogs
WO2010045442A1 (en) 2008-10-15 2010-04-22 Infinity Discovery, Inc. Ansamycin hydroquinone compositions
JPWO2011040421A1 (ja) 2009-09-29 2013-02-28 武田薬品工業株式会社 スクリーニング方法
CA2789879A1 (en) 2009-10-28 2011-05-19 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
JP5892939B2 (ja) 2009-11-02 2016-03-23 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 細胞状態をモニタリングするための方法及び間葉系幹細胞を不死化するための方法
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
LT2699580T (lt) 2011-04-22 2018-01-10 Joyant Pharmaceuticals, Inc. Diazonamido analogai
EP2904119B1 (en) 2012-10-02 2020-06-17 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
WO2015140005A1 (en) 2014-03-19 2015-09-24 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Method of generation of pluripotent cells
WO2018070939A1 (en) 2016-10-12 2018-04-19 Agency For Science, Technology And Research Method for lyophilising an exosome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987035A (en) * 1974-04-05 1976-10-19 University Of Illinois Foundation Biologically active compounds
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug

Also Published As

Publication number Publication date
EP0693073B1 (en) 1998-06-03
CA2160137A1 (en) 1994-10-13
FI106028B (sv) 2000-11-15
DE69410790T2 (de) 1998-10-01
DK0693073T3 (da) 1998-10-12
FI941580A (sv) 1994-10-08
JP2722280B2 (ja) 1998-03-04
ES2116594T3 (es) 1998-07-16
CA2160137C (en) 1999-02-09
DE69410790D1 (de) 1998-07-09
JPH08503960A (ja) 1996-04-30
EP0693073A1 (en) 1996-01-24
US5387584A (en) 1995-02-07
ATE166877T1 (de) 1998-06-15
WO1994022867A1 (en) 1994-10-13

Similar Documents

Publication Publication Date Title
FI941580A (sv) Bicykliska ansamyciner
DK0873340T3 (da) Heterocyklisk substituerede cyclopentanforbindelser
DK0705100T3 (da) Terapeutiske substituerede guanidiner
ATE243694T1 (de) 4-mercaptoacetylamino-(2)benzazepinon(3)- derivate, und verwendung als enkephalinase- inhibitoren
DE69620161D1 (de) Thrombininhibitoren
DE69528528D1 (de) Thrombin-inhibitoren
ATE217629T1 (de) Phosphonooxymethyl oder methylthiomethylether von taxanderivaten als antitumormittel
TR199800773T2 (xx) Trombin inhibit�rleri.
TW225534B (sv)
HU9500559D0 (en) New mercapto-acetamide tricyclic derivatives as enkephalinase-inhibitors
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
GR3029454T3 (en) Novel 9-n-bicyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines

Legal Events

Date Code Title Description
MA Patent expired